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Abstract
Platelets modulate the process of cancer metastasis. However, current knowledge on the
direct interaction of platelets and tumor cells is mostly based on findings obtained in vitro. We
addressed the role of the platelet fibrinogen receptor glycoprotein IIb (integrin αIIb) for experi-
mental melanoma metastasis in vivo. Highly metastatic B16-D5 melanoma cells were injected
intravenously into GPIIb-deficient (GPIIb-/-) or wildtype (WT) mice. Acute accumulation of
tumor cells in the pulmonary vasculature was assessed in real-time by confocal videofluores-
cence microscopy. Arrest of tumor cells was dramatically reduced in GPIIb-/- mice as com-
pared to WT. Importantly, we found that mainly multicellular aggregates accumulated in the
pulmonary circulation of WT, instead B16-D5 aggregates were significantly smaller in GPIIb-/-
mice. While pulmonary arrest of melanoma was clearly dependent on GPIIb in this early
phase of metastasis, we also addressed tumor progression 10 days after injection. Inversely,
and unexpectedly, we found that melanoma metastasis was now increased in GPIIb-/- mice.
In contrast, GPIIb did not regulate local melanoma proliferation in a subcutaneous tumor
model. Our data suggest that the platelet fibrinogen receptor has a differential role in the mod-
ulation of hematogenic melanoma metastasis. While platelets clearly support early steps in
pulmonary metastasis via GPIIb-dependent formation of platelet-tumor-aggregates, at a later
stage its absence is associated with an accelerated development of melanoma metastases.
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Introduction
Hematogenic tumor cell dissemination is the leading cause of death in patients with malignant
melanomas. The lung is among the most common sites of melanoma metastasis [1], while extra-
pulmonary metastases usually do not occur prior to lung metastasis [2]. Melanoma patients
with lung metastases have a 5-year survival rate of below 10% [3]. Hence, strategies targeting
hematogenic melanoma cell spreading are considered promising in order to improve the overall
outcome of melanoma patients [4]. Hematogenic tumor cell dissemination engages a multi-step
process. Once released from the primary tumor, metastatic cells invade the vasculature and
travel in the blood stream to reach their target organs. Tumor cell dissemination is a highly inef-
ficient process as more than 99% of tumor cells are rapidly eliminated in the circulation [5]. In
order to survive, circulating tumor cells have to be retained within organs. Upon arrest, they
transmigrate into the perivascular matrix, where they proliferate and may ultimately lead to the
clinical manifestation of cancer metastasis [6].
Several studies have linked platelets to hematogenic tumor cell dissemination in various
malignancies [7, 8](reviewed in [9]), however, the exact role of platelets has remained contro-
versial. It has been shown that platelets directly interact with certain tumor cells under both
static and low flow conditions [7, 8, 10, 11]. In addition, studies mostly performed in vitro sug-
gest that platelets promote tumor cell arrest on subendothelial matrices [8, 12], and foster
tumor cell proliferation [13]. Platelets are also essential for regulating the hemostasis of tumor
vasculature and for preventing intratumoral hemorrhage [14]. Recently, platelets have been
demonstrated to impair natural killer (NK) cell-mediated elimination of tumor cells by bind-
ing to tumor cell surfaces [15, 16]. Although these findings suggest a supportive role for plate-
lets in tumor cell spreading and growth, the exact contribution and biological relevance of
platelets for metastasis is still unclear. While some studies have shown that targeting of platelet
membrane receptors, such as glycoprotein (GP)IIb-IIIa, by monoclonal antibodies or elimina-
tion of circulating platelets results in a significant reduction in the number of metastases in
transplantable murine tumor models [11, 17], others report that inhibition of platelet receptors
does not confer protection against tumor cell dissemination or rather increases metastasis for-
mation. In fact, inhibition of platelet GPIbα was demonstrated to enhance hematogenic cancer
metastasis [18, 19]. While the number of pulmonary metastases was the major endpoint in
most of the above studies, they differ substantially with respect to the timing and duration of
inhibition of platelet membrane receptors. Based on the discrepant findings in different exper-
imental settings, platelet receptors possibly have opposing effects on the different steps of ini-
tial tumor cell dissemination and subsequent tumor cell proliferation during metastasis
formation. However, their role for distinct steps in the process of hematogenic tumor cell
metastasis in vivo has not been addressed in detail to date. In addition, transgenic mice defi-
cient in GPIIb-IIIa, which resemble the phenotype of human Glanzmann thrombasthenia
[20], have not been studied in this context, and determining hematogenic metastasis in such
mice seems of broad interest [21].
In the present study, we dissected the role of platelet αIIb integrin (GPIIb) for early and late
steps in pulmonary melanoma metastasis. We first addressed in vitro potential mechanisms
for initial recruitment of circulating melanoma cells to vascular endothelium using a flow
chamber model and then assessed the role of GPIIb for metastasis formation in vivo in mice
lacking integrin αIIb (GPIIb-/-) [20]. GPIIb associates with GPIIIa (integrin β3) to form the
platelet-specific integrin heterodimer GPIIb-IIIa (integrin αIIbβ3), representing the most
abundant platelet surface receptor and predominantly functioning as platelet fibrinogen recep-
tor. By binding to fibrinogen, but also to von Willebrand factor, GPIIb-IIIa mediates cross-
linking of adjacent platelets, resulting in platelet aggregation and platelet secretion of
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chemokines as well as growth factors [22, 23]. Moreover, binding of GPIIb-IIIa to fibronectin,
vitronectin or PECAM-1 leads to platelet adhesion to the vessel wall [24]. In order to follow
the initial steps of tumor metastasis in wildtype (WT) and GPIIb-deficient mice, we applied a
novel microscopic approach using a fluorescence optical imaging system based on laser scan-
ning confocal technology. We show that the acute retention of malignant melanoma cells is
dramatically reduced in mice deficient in platelet GPIIb. We also found that GPIIb has a
minor effect of adhesion of single melanoma cells, but rather mediates the formation of plate-
let-rich melanoma cell aggregates, which are retained in the pulmonary vasculature. Despite
defective initial tumor cell accumulation, mice lacking GPIIb were not protected from pulmo-
nary metastasis formation, but rather revealed a significant increase in metastatic tumor
growth and proliferation in the lung 10 days after melanoma injection. Together, this provides
evidence that platelet GPIIb contributes to initial tumor cell arrest at the early stage of tumor
cell dissemination, but prevents subsequent metastatic tumor growth and/or survival.
Material and methods
Animals
All mice were on C57BL/6J background. GPIIb-/- mice (αIIb-integrin)-deficient mice were
generated as described previously [20]. Age- and sex-matched GPIIb+/+ (WT) littermates
served as controls. Animals were housed in specific pathogen free conditions in individually
ventilated type III cages from TECNIPLAST (Hohenpeißenberg, Germany). Mice received
standard chow from Altromin (Lage, Germany) and sterile tap water ad libitum. Appropriate
enrichment (plastic-houses from TECNIPLAST, sterile pulp paper and coarsely litter) was pro-
vided. Physical condition of mice was monitored twice daily. A protocol approved by the Gov-
ernment of Bavaria for early euthanasia of potentially ill or moribund mice was in place. All
experimental procedures on animals met the requirements of the German legislation on pro-
tection of animals and were approved by the Government of Bavaria, Germany.
Antibodies
For evaluation of melanoma surface molecule expression by flow cytometry, PE-conjugated
rat anti-mouse αv-monoclonal antibody (mAb) (clone RMV-7), anti-β3-mAb (clone HM
beta3.1) and rat IgG2a-isotype control were obtained from BD Pharmingen (Heidelberg, Ger-
many). anti-αIIb-mAb (clone MWReg 30) was obtained from eBioscience. FITC-conjugated
mouse anti-human αvβ3-mAb (clone LM609) was purchased from Chemicon, mouse anti-
human αIIb-mAb (clone P2) from Immunotec (Beckam Coulter, Krefeld, Germany) and IgG
isotype control (X 0927, X 0928) from Dako (Glostrup, Denmark). For evaluation of platelet
surface molecule expression by flow cytometry, anti-β3-mAb (BD Biosciences, clone 2C9.G2),
anti-αIIb-mAb (eBioscience, clone MWReg30), GPIb (Emfret Analytics, clone X488), GPVI
(Emfret Analytics, clone JAQ1), GPIX (Emfret Analytics, clone Xia.B4), anti-P-Selectin anti-
body (BD Biosciences, clone RB40.34), Annexin V (BD Pharmingen) and respective isotype
controls were used. For fluorescence microscopy, polyclonal FITC-conjugated anti-GFP and
goat rhodamine-conjugated anti-PE secondary antibody from Rockland (Gilbertsville, PA,
USA), anti-ki67-PE (clone B56) from BD Biosciences (Cat. No. 556027, Germany), rabbit
polyclonal anti-fluorescein/Oregon Green IgG (Molecular Probes, Karlsbad, CA, USA), rat
anti-mouse αIIb-mAb (clone MWReg 30, BD Pharmingen), and anti-rat Alexa Fluor 488 and
Alexa Fluor 594 (Molecular Probes) were purchased. For flow chamber experiments, c7E3 Fab
(ReoPro) was obtained from Lilly (Bad Homburg, Germany).
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Evaluation of platelet surface molecule expression
Expression of platelet surface molecules was investigated in washed murine platelets. Whole
blood was obtained from GPIIb+/+ and GPIIb-/- mice by puncture of the inferior vena cava
and anticoagulated with sodium citrate. Whole blood was washed and centrifuged in the pres-
ence of 0.5 μg prostaglandin. Washed platelets were resuspended in Tyrode’s buffer. Resting
washed platelets were incubated with antibodies indicated above and surface expression was
measured by flow cytometry. Surface P-Selectin- and AnnexinV/PS-exposure was determined
in resting and Thrombin (0.05 U/mL, 10 min) stimulated platelets.
Cell culture
B16-D5 mouse melanoma cells, a poorly immunogenic subclone of the spontaneously arising
B16-BL6 melanoma, were kindly provided by Dr. Winter (Franz Cancer Research Center, Earle
A. Chiles Research Institute, Portland, OR) [25, 26]. αvβ3-positive M21 and αvβ3-negative
M21L human melanoma cells were kindly provided by Prof. Dr. Haubner (Dep. of Nuclear
Medicine, Medical University of Innsbruck, Austria) [27]. Cryo-preserved pooled primary
human umbilical vein endothelial cells (HUVEC) were obtained from Promocell (Heidelberg,
Germany) and cultured as described [28]. Cells were grown until confluence, and either left
untreated (resting) or stimulated with 50 ng/mL TNF-α and 20 ng/mL IFN-γ for 20 hours
before flow chamber experiments were performed.
Intravital microscopy
Mice were anesthetized by intraperitoneal application of Midazolam (10mg/kg body weight,
Ratiopharm, Ulm, Germany), Medetomidin (1mg/kg, Pfizer, Karlsruhe, Germany) and Fenta-
nyl (0,2mg/kg, Curamed Pharma, Munich, Germany). A polyethylene catheter was introduced
into the left jugular vein. Upon tracheotomy mice were intubated and mechanically ventilated
(MiniVent Typ 845, Hugo Sachs Electronics, March, Germany) at 120 strokes/minute and
150μl stroke volume of 0,5% isofluran-oxygen ratio [29]. Subsequently, a partial right thoracot-
omy with costal resection was performed to exhibit an oval lung field of approximately 1,5 x 2
cm2. To minimize movements of the diaphragma, which readily conduct to the lung, the right
phrenical nerve was anesthetized by local application of 1% Lidocaine (B. Braun, Melsungen,
Germany). B16-D5 cells were labeled with 5-carboxyfluorescein diacetate succinimidyl ester
(DCF) and adjusted to 1x105 cells in 250μl Tyrodes buffer. DCF-tagged B16-D5 were intrave-
nously infused in syngeneic mice on C57BL/6J background. For experiments conducted in
vivo, GPIIb-/- mice and their sex-matched GPIIb+/+ littermates were handled as treatment
pairs, thus receiving cells from the same preparation. In another set of experiments, 1.5x108
isolated WT or GPIIb-/- platelets were administered into GPIIb-/- mice prior to B16-D5 appli-
cation where indicated. Immediately and 1 hour after B16-D5 application the B16-D5 arrest in
the pulmonary vasculature was monitored in vivo. Using confocal laser scanning fibre bundle
microscopy [30] (CellvizioTM, Mauna Kea Technologies, Paris, France) we directly visualized
the DCF-tagged tumor cells in vivo (S3 Fig). A flexible fibre bundle microprobe (MiniO Pro-
flex microprobe, diameter 300μm, Mauna Kea) with a maximal optical penetration depth of
150μm was placed on the lung surface. The vasculature of the dorsal, ventral and basal pulmo-
nary margin of each mouse was visualized in identical chronological order and direction. All
images were taken during a ventilation pause following exhalation. Videos were recorded in
real-time at a speed of 12 frames per second for subsequent analysis. To quantify melanoma
retention in the lung, the number of retained tumor cell clusters was counted in the total range
of the dorsal, ventral and basal right pulmonary margin from the recorded videos. To evaluate
the size of accumulated tumor cell aggregates in the pulmonary vasculature, the first 10 events
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imaged at the dorsal margin were selected and their area was subsequently assessed using com-
puter-assisted image analysis software (CapImage, Dr. Zeintl, Heidelberg, Germany).
Evaluation of B16-D5 metastasis formation
To determine the effect of GPIIb-IIIa mediated platelet action on metastasis formation in the
lung, 1x105 B16-D5 were infused into the jugular vein of GPIIb+/+ (WT) or GPIIb-/- mice. As
described above, GPIIb-/- mice and their sex-matched GPIIb+/+ littermates were studied as treat-
ment pairs. 10 days later, animals were euthanized by cervical dislocation and the number of
metastatic nodules on the surface of the right lung was counted by blinded staff, and thereafter
processed for histological analysis as described below. In addition, mRNA was isolated from the
left lung of the same animal and pre-melanosomal protein (Pmel; Mus musculus 16756-Si: Sil-
ver) expression was quantified using Real-Time PCR (Quantitec Primer Assay, QT00102487,
Qiagen, Hildesheim, Germany). Total mRNA was isolated with the RNeasy Midi Kit (Qiagen)
following manufacturer’s instructions, and further reverse transcribed into cDNA using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany).
Quantitative Real-Time PCR was performed with SYBR Green (Fermentas, Leon-Rot, Germany)
as a fluorescent dsDNA-binding dye and Pmel expression was quantified by the ΔCt-Method
after normalization to a housekeeping gene (beta-actin). All reactions were run as triplicates.
Histology
1) Histological analysis of GFP+ B16-D5 interaction with platelets: Lung specimens were
obtained after injection of 0.5x106 GFP+ B16 and incubated overnight at 4˚C in a fixative con-
taining 0.01M sodium periodate, 0.075M L-lysine and 1% paraformaldehyde. Thereafter, tis-
sues were washed with 0.1M phosphate buffer, passed through sucrose gradient solutions and
embedded in OCT compound (TissueTek1, Sakura, Netherlands). Cryostat sections (7 μm)
were stained with the following reagents: 4’,6-Diamidino-2-phenylindol (DAPI), rat anti-
mouse GPIIb (CD41) and an Alexa Fluor 594-conjugated anti-rat antibody. To enhance the
GFP-signal of B16-D5 we used a FITC-conjugated anti-GFP antibody (Rockland, Rockland,
PA). Stained sections were mounted in Prolong Gold anti-fade mounting medium (Thermo
Fisher Scientific, Waltham, MA).
2) Ki67 staining of lung specimen. After determining colonization, lungs were fixed in 10%
neutral buffered formalin solution, dehydrated and embedded in paraffin. 20 sections of 3 μm
thickness with 50 μm distance were generated from each lung. The sections were rehydrated
and heat induced antigen retrieval was achieved by cooking the slides in citrate buffer (pH 6).
Fc-blockade (BD Bioscience) was performed for 30 minutes. For sequential double immunoflu-
orescence analysis sections were first treated with anti-ki67 PE (BD Biosciences) and a goat rho-
damine-conjugated anti-PE secondary ab (Rockland), and then with an anti-HMB-45 mAb
(Agilent, Santa Clara, CA) and a goat anti-mouse Alexa-488 secondary ab (Invitrogen™, Thermo
Fisher Scientific), and DAPI. For detection of melanoma cells within the pulmonary tissue we
applied the mouse anti-human antibody HMB-45 raised against the melanoma-specific marker
Pmel. Human and mouse Pmel17/gp100 proteins have 79.7% amino acid sequence homology
[31]. The mAb HMB-45 thus recognizes a shared epitope between both species, and murine
B16 melanoma cell lines expressing Pmel17 demonstrated consistent staining with HMB-45
[32, 33]. Sections were investigated using a Leica DMRB epifluorescence microscopy.
Role of GPIIb for tumor growth
Wild-type and GPIIb-deficient mice were anesthetized and their back was shaved. 105 B16-D5
cells in 200ul PBS were injected subcutaneously into the skin of the right flank. From day 14
Platelet GPIIb modulates melanoma metastasis
PLOS ONE | DOI:10.1371/journal.pone.0172788 March 2, 2017 5 / 20
after subcutaneous implantation, tumor diameters were measured every other day using a cali-
per. The tumor was explanted on day 21 post-injection and its weight was measured. The
majority of mice from both genotypes developed a visible tumor within few days. Three mice of
each genotype did not develop significant tumors during the whole duration of the experiment.
Assessment of platelet-tumor interactions under flow conditions
1) Interaction of human platelets with M21 melanoma cells. Whole blood was drawn from
healthy donors and platelets were isolated as described [28]. All blood donors were volunteers
who gave their free and informed written consent to this research study, which conforms to
the ethical standards of the Declaration of Helsinki. Approval was obtained from the Technical
University of Munich institutional review board for these studies. Flow chamber experiments
were basically performed as reported earlier [28]. In brief, HUVEC were cultivated to con-
fluency on glass cover slips for usage in a flow chamber, and either left untreated or co-stimu-
lated with 50 ng/mL TNF-α and 20 ng/mL IFN-γ for 20 hours. HUVEC were perfused with
DCF-labeled M21 or M21L at a shear rate of 1000/s for 10 minutes in the presence or absence
of platelet-rich plasma or washed human platelets. To block GPIIb-IIIa receptor specific
action, melanoma cells or the platelet-melanoma cell suspensions were preincubated with the
monoclonal antibody abciximab (c7E3 Fab, 4 μg/mL; Lilly Deutschland, Bad Homburg, Ger-
many) for 15 minutes. Tumor-endothelium interaction and tumor aggregate formation was
studied in a flow chamber system mounted on the stage of an Axiovert 100 (Zeiss, Jena, Ger-
many) microscope. All images were videotaped and subsequently evaluated offline using a
computer-assisted image analysis program (Cap Image 7.1, Dr. Zeintl, Heidelberg, Germany).
The number of firmly adherent melanoma cells was assessed by counting the cells that did not
move or detach from the endothelial monolayer within 20 seconds. Further, the number of
tumor cells within platelet-melanoma-aggregates was quantified.
2) Interactions of murine platelets with B16 melanoma cells. Whole blood was drawn from
mice by cardiac puncture and platelets were isolated as described [34]. 106 B16 cells were per-
fused together with 108 washed murine platelets for 20min at 37C. Calcium (1mM), magnesium
(1mM) and fibrinogen (Sigma, 75 μg/ml) were supplemented [35]. Perfusion was performed at
1000/s in a closed flow chamber system allowing recirculation of cells at continuous unidirec-
tional and pulsatile flow (Ibidi, Martinsried, Germany). Platelet tumor aggregate formation was
determined by flow cytometric analysis of platelet (glycoprotein Ib, CD42) positive cells (as
compared to PE-isotype control) within the B16-population. Data was quantified on a FACS
Calibur(Becton Dickinson, Franklin Lakes, NJ) and evaluated using FlowJo v10, LLCsoftware
(Ashland, OR)
Determination of platelet-tumor cell aggregate formation in vitro
M21 melanoma cells were incubated for 15 minutes in the absence and presence of platelet-rich
plasma and subsequently analyzed by fluorescence and electron microscopy. For fluorescence
microscopy, probes were stained with fluorescent-labeled phalloidin and fluorescent antibodies
directed against CD41 and fibrinogen. For electron microscopy (EM), cells were fixed in a
sodium-cacodylate buffer (pH 7.4) with glutaraldehyde (2.5%) and tannin (0.02%). For scanning
EM (SEM) fixed cells were plated on coverslips, and for transmission EM (TEM) probes were
embedded in epoxyresin. Electron microscopy was performed as previously described [36].
Statistics
Prism 5.0 (GraphPad, San Diego, CA) was used as statistical software. Data are presented as
means ± SEM unless stated otherwise. For in vivo experiments with matched treatment pairs
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data were analyzed using Student’s paired two-sample t-test. Other data was analyzed using
the Tukey-test or one-way analysis of variance (ANOVA) with a Tukey posthoc test where
adequate. A value of P < 0.05 was regarded as significant.
Results
Platelet-melanoma interaction under flow conditions
Adhesion of tumor cells in the target vasculature is the initial step of metastatic seeding. Acti-
vated platelets have recently been shown to promote tumor cell adhesion to endothelial cells in
vitro under venous flow conditions [8, 10]. However, in the in vivo setting, tumor cells are
exposed to higher shear forces and are likely to encounter mostly non-activated platelets.
Therefore, we first addressed whether unstimulated platelets–similar to collagen-activated
platelets [8]–are also able to promote tumor cell adhesion, when exposed to capillary flow in
vitro. Yet, when we applied shear conditions resembling those prevailing in the pulmonary
microcirculation [37], only few M21 human melanoma cells, and even less M21L melanoma
cells, lacking the major adhesion receptor αvβ3 [27], adhered to resting endothelial cells under
flow (Fig 1A, left image and Fig 1B). Addition of non pre-activated platelet-rich plasma did
not increase the number of adherent melanoma cells (Fig 1A, middle image and Fig 1B). Only
when we co-stimulated endothelial cells with 50ng/mL TNF-α and 20ng/mL IFN-γ for 20
hours adhesion of melanoma cells was significantly increased (Fig 1B). Yet again the presence
of platelets did not significantly increase, but rather reduced the adhesion of tumor cells to the
endothelial monolayer (Fig 1B). Together, this suggests that non pre-activated platelets are dis-
pensable for adhesion of single melanoma cells to endothelial cells under capillary flow
conditions.
Formation of platelet-rich tumor cell aggregates in vitro
Previous in vitro data have identified that platelets bind to melanoma cells in a process involv-
ing platelet GPIIb-IIIa, fibrinogen and tumor cell-expressed αvβ3 integrin [8]. We hypothe-
sized that rather than promoting tumor cell adhesion, GPIIb-IIIa mediates the formation of
platelet–melanoma cell aggregates. In a first step, we analyzed in vitro whether platelet–mela-
noma cell aggregate formation occurs under flow. We perfused M21 and M21L in the presence
or absence of platelets over a confluent endothelial monolayer applying capillary flow condi-
tions. We found that in the absence of platelets, melanoma cells circulated as single cells, while
aggregates of M21 cells (~6% of perfused melanoma cells), or αvβ3-deficient M21L cells were
barely observed (<3% of perfused melanoma cells) (Fig 1A, left image, 1C and 1D). In con-
trast, in the presence of platelets, aggregate formation of M21 was significantly increased;
approximately 20% of all melanoma cells were now incorporated into aggregates (Fig 1A, mid-
dle image and Fig 1C and 1D). When we examined the size of aggregates, we found that the
few aggregates which formed in the absence of platelets mostly consisted of two cells, whereas
larger aggregates were rarely detected (Fig 1D). In contrast, when platelets were added to/co-
perfused with M21 cells, the aggregate size significantly increased; in fact, the number of aggre-
gates containing 3–4 cells was approximately 5-fold higher in the presence of platelets, when
compared to M21 cells in the absence of platelets. We even frequently found large aggregates
comprising >5 cells in the presence of platelets (Fig 1D). Further analysis of the melanoma cell
aggregates by immunofluorescence and electron microscopy revealed that platelets physically
participated in melanoma cell aggregation. We observed numerous platelets/platelet aggre-
gates interspersed between the assembled melanoma cells (Fig 1E–1G). The heterotypic plate-
let-melanoma cell aggregation under flow required GPIIb-IIIa. Correspondingly, aggregate
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formation was strongly reduced in the presence of the antibody c7E3 Fab targeting both
GPIIb-IIIa and the vitronectin receptor αvβ3 integrin (Fig 1A, right image, Fig 1C and 1D).
We added another set of experiments to determine whether in murine cells GPIIb integrin
also plays a role in platelet-tumor aggregate formation under capillary flow conditions. To do
so, we isolated platelets from GPIIb+/+ and GPIIb-/- mice and co-perfused them with murine
B16-D5 melanoma cells in the presence of fibrinogen in a closed flow chamber system [35].
Consecutive quantification by flow cytometry analysis revealed that also in the murine system
platelet-B16 aggregate formation was enhanced in the presence of GPIIb (Fig 1H and 1I). To
test whether GPIIb-deficiency alters platelet surface receptor expression, flow cytometry was
performed with isolated GPIIb+/+ and GPIIb-/- platelets. We found no difference in surface
expression of glycoprotein GPIb-IX-V complex or GPVI receptor in GPIIb-/- platelets com-
pared to GPIIb+/+ controls. Further no difference in P-Selectin or Annexin V expression could
be detected upon thrombin activation (S2A–S2C Fig). Taken together, these findings implicate
that under in vitro capillary flow conditions non pre-activated platelets do not promote adhe-
sion of single melanoma cells to endothelial cells, but rather trigger the formation of platelet-
tumor cell aggregates which is in part dependent on GPIIb-IIIa integrin. Flow chamber assays,
however, are not capable of resembling the complex in vivo capillary flow conditions, such as
alternating shear rates, tube diameters or variable site densities of endothelial adhesion mole-
cules which all may influence melanoma cell adhesion and aggregation behavior [38, 39].
Hence, we designed mouse experiments to define whether platelet-melanoma cell aggregate
formation also occurs in vivo and whether this mechanism is of any relevance for pulmonary
metastasis.
Circulating platelet-melanoma aggregates form in vivo and are retained
in the pulmonary vasculature
To evaluate intravascular conglomeration of melanoma cells, we infused 0.5 x 106 GFP-
expressing B16-D5 into the jugular vein of anaesthetized, spontaneously breathing WT mice.
One hour after B16 application, citrated blood was carefully drawn from the right ventricle
and lungs were harvested. Using flow cytometry, we determined numerous CD41-positive
platelets attached to GFP+ B16-D5 in mouse whole blood (figure not shown), suggesting that
platelet-induced melanoma-aggregate formation occurs under flow both in vitro and in vivo.
When we examined the lungs of these animals one hour after infusion of GFP+ B16-D5 mela-
noma cells, we found large aggregates consisting of B16-D5 cells and platelets within the lung
Fig 1. Platelet-tumor-endothelium interaction under flow. a) Photomicrographs show platelet and M21 aggregate formation under
flow (1000/s). Co-perfusion of platelets and M21 cells induced formation of aggregates which did not firmly adhere and are therefore
only partly focused (middle picture; arrows indicate platelet-M21 aggregates). Aggregation is virtually abolished in the absence of
platelets (left picture) or the presence of c7E3 Fab (right picture). Bars 0.2mm. Images were taken using a Zeiss Axiovert 100
microscope, 20x objective. b) HUVEC (resting or TNF-α/IFN-γ-stimulated) were perfused with M21 or αv-deficient M21L melanoma
cells, that lack the expression of both αvβ3 and αvβ5 integrins, in the absence and presence of platelet-rich plasma (10min, shear rate
1000/s). Results are shown as number of firmly adherent M21 and M21L (n = 5; *P<0.05 for M21 vs. M21+PRP on activated HUVEC).
c) Frequency of M21 and M21L aggregates in the absence and presence of platelets and c7E3 antibody. Results are given as number
of melanoma cell-aggregates in % of all perfused tumor cells (n = 5; *P<0.001 for M21 in the absence vs. presence of platelets). d)
Size distribution of M21 aggregates in the absence and presence of platelets and c7E3. e-g) M21 melanoma cells were incubated for
15 minutes in the absence and presence of platelet-rich plasma. e) Scanning electron microscopy indicates single melanoma cells in
the absence (left picture) and melanoma cell aggregates in the presence of platelets (right picture). Bars, 5μm. f) Transmission
electron microscopy indicates direct platelet-melanoma interaction. Bar, 1μm. g) Photomicrographs show representative fluorescence
microscopy images of M21-platelet aggregates stained with phalloidin (red) and anti-GPIIb (CD41) mAb (green). Bars, 20μm. Images
were taken using a Leica DMRB epifluoresence microscope, 20x objective. h-i) Analysis of mouse GPIIb-/- or WT platelet interaction
with B16 melanoma under flow conditions (1000/s). h) Percentage of platelet-positive B16 cells (n = 4; *P<0.05). i) Representative
FACS contour plots indicate CD42-staining on B16 cells in the absence (control) and presence of GPIIb+/+ or GPIIb-/- platelets.
doi:10.1371/journal.pone.0172788.g001
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capillary network (Fig 2A). Thus, platelet-dependent aggregate formation in the blood and
lungs is an early event after tumor cell infusion into mice in vivo.
Determination of melanoma cell-aggregate embolization in the
pulmonary microcirculation using IVM
Based on the above findings we hypothesized that rather than adhesion of individual tumor
cells, the platelet-dependent formation of melanoma cell-aggregates and their subsequent
retention within the pulmonary circulation triggers efficient metastatic melanoma cell seeding.
In order to address this hypothesis, we analyzed in vivo whether blood-borne tumor cell-plate-
let aggregates can indeed be trapped within the pulmonary microcirculation. We therefore
directly visualized the recruitment of melanoma cells in the pulmonary vasculature using real-
time in vivo confocal microscopy (IVM) of the mouse pulmonary vasculature (S3 Fig). DCF-
labeled B16-D5 cells were administered into the jugular vein of anaesthetized and mechani-
cally ventilated WT and GPIIb-/- mice. Immediately after cell infusion, numerous melanoma
cells accumulated in the WT lung vasculature. IVM revealed that B16-D5 melanoma cells are
rarely recruited to the WT pulmonary circulation as single cells, but mostly accumulate in the
form of multicellular aggregates captured in larger vessel (S1 Videos). In several occasions
B16-D5 were entrapped at vascular bifurcations. In contrast, significantly less melanoma cells
accumulated in pulmonary vessels of GPIIb-/- mice within the first minutes after infusion (Fig
2B). Moreover, when we quantified the size of B16-D5 conglomerates, we found that there was
not only a decrease in the overall number of retained aggregates but also that B16-D5 aggre-
gates were significantly smaller in GPIIb-/- mice compared to WT animals (Fig 2B and 2C).
The difference between WT and GPIIb-/- mice was even more pronounced 1 hour after
B16-D5 administration (Fig 2B and 2C). This suggests that a substantial proportion of those
melanoma cells initially retained in GPIIb-/- mice was able to pass the pulmonary microcircu-
lation after prolonged transit times.
GPIIb-IIIa has been considered to be expressed exclusively on cells derived from the mega-
karyocytic/platelet lineage. However, recent evidence suggests that also some tumor cell lines
surface express GPIIb-IIIa [40, 41]. Nevertheless, when we performed flow cytometry we
found that neither B16-D5 nor M21 melanoma cells expressed GPIIb (S1 Fig). In order to
exclude that GPIIb-IIIa from additional (non-platelet, non-melanoma cell) sources contributes
to melanoma cell-aggregate formation and retention in vivo, we performed an additional set of
experiments in which GPIIb-/- mice were treated with GPIIb-/- or WT platelets prior to admin-
istration of DCF-labeled B16-D5. After 1 hour, IVM of the pulmonary vasculature was per-
formed as described above. When WT platelets were infused into GPIIb-/- mice we now
observed an increase in number of tumor cells that accumulated in the pulmonary vasculature
compared to GPIIb-/- mice receiving GPIIb-/- platelets (Fig 2E and 2F). This indicates that mel-
anoma cell recruitment in the pulmonary microcirculation is mediated by platelets and
depends on platelet GPIIb-IIIa. At the same time this set of experiments makes it unlikely that
in GPIIb-/- mice a pulmonary phenotype restricts tumor cell accumulation.
Taken together, our in vivo imaging revealed that platelet-melanoma cell coaggregation
rather than adhesion of single melanoma cells is essential for their initial capturing in the pul-
monary circulation. This mechanical entrapment of large platelet-tumor cell aggregates could—
at least in part—explain the pulmonary tropism of malignant melanoma.
Role of platelet GPIIb for melanoma metastasis after 10 days
We next aimed to further dissect the relevance of platelet GPIIb-mediated events in hemato-
genic melanoma cell metastasis beyond the acute effects on tumor cell arrest. To do so, we
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intravenously infused B16-D5 cells into WT and GPIIb-/- mice. Ten days later the right lungs
were harvested and the numbers of metastases counted in situ. Unexpectedly, we observed
that despite the defect in initial melanoma cell retention in GPIIb-/- mice, the mutants were
not protected from metastasis formation at later stages. In fact, the number of metastases was
significantly lower in lungs of GPIIb+/+ littermates compared to GPIIb-/-mutants (Fig 3A–3C).
In order to further evaluate the tumor load ten days after B16-D5 application, we analyzed
the expression of melanoma cell specific antigen Pmel17/silver in the lungs. In line with mac-
roscopic findings, mRNA expression of Pmel17/silver revealed an attenuated tumor load in
GPIIb+/+ mice as compared to their GPIIb-/- littermates (Fig 3C).
Taken together, these findings have three major implications: (1) a GPIIb-IIIa mediated
platelet mechanism is essential to allow initial tumor cell retention in the pulmonary vascula-
ture; (2) despite favoring initial melanoma cell retention, GPIIb-IIIa-mediated platelet activity
suppresses subsequent tumor growth at later stages after initial seeding; (3) consistent with
recent findings in the brain microcirculation [6] our present observations in the lung indicate
that initial seeding and micrometastasis formation are not inevitably linked to efficient growth
to macrometastases.
Reduced melanoma proliferation in the presence of platelets and GPIIb
To address this apparent discrepancy and to further evaluate our observation that a platelet
GPIIb-dependent mechanism inhibits melanoma growth after initial seeding, we checked for
melanoma cell proliferation rates 10 days after melanoma cell injection using Ki67 staining on
lung sections. For identification of melanoma cells within the pulmonary tissue we used the anti-
body HMB-45 raised against the melanoma-specific marker Pmel. We found that in GPIIb-/-
mice significantly more melanoma cells were Ki67 positive compared to their GPIIb+/+ litter-
mates (Fig 3D and 3E, S4 Fig). This indicates that the presence of GPIIb suppresses tumor cell
proliferation in our model of melanoma metastasis formation.
To address whether platelets can directly influence melanoma growth, we next performed
cell culture experiments of melanoma cells in the presence or absence of washed platelets. We
studied incorporation of the thymidine analog bromodeoxyuridine (BrdU) as a marker for
DNA synthesis and cell proliferation. We found that M21 melanoma proliferation was signifi-
cantly reduced by addition of isolated human platelets. Notably, the effect was dose-dependent
as incubation with increasing platelet numbers resulted in greater inhibition of tumor growth
(Fig 3F). Thus, platelets, which accumulated in high numbers around melanoma cells in vitro
(Fig 1A–1I) and in vivo (Fig 2A), increased initial tumor cell arrest and metastasis formation
in vivo (Fig 2B–2D), but negatively regulated tumor cell proliferation (Fig 3D–3F).
Fig 2. Platelet-tumor-aggregate formation in vivo. a) GFP-transfected B16-D5 melanoma cells were injected intravenously into
wildtype mice. After 1 hour, lung tissue was obtained for immunofluorescence analysis. Photomicrographs show mouse lung tissue
stained with antibodies directed against platelet GPIIb (CD41, red) and B16-D5 (GFP, green); nuclei were stained with DAPI (blue). Bars,
40μm. Images were taken using a Leica DMRB epifluoresence microscope, 20x objective. b-d) Arrest of DCF-tagged B16-D5 melanoma
cells was visualized in the pulmonary vasculature by intravital confocal videofluorescence microscopy (IVM) in GPIIb+/+ and GPIIb-/-
littermate mice immediately and after 1 hour. b) Number of metastatic events was quantified. Results are given as percentage of firmly
adherent B16-D5 in GPIIb-/- mice compared to its WT littermate (n = 5–6 experiments per group; *P<0.01 acute; **P<0.001 after 1 hour).
c) Size of B16-aggregates was quantified. Results are given as percentage of B16-aggregate size in GPIIb-/- mice compared to its WT
littermate (n = 5–6; *P<0.05 after 1 hour). d) Photomicrographs show representative IVM images obtained in GPIIb+/+ and GPIIb-/-. In
GPIIb+/+ mice, arrest of large multicellular aggregates is frequently observed (left). Arrest of DCF-tagged B16-D5 is visualized in precapillary
vessels (right). Bars, 20μm. d e-f) GPIIb+/+ (WT) or GPIIb-/- platelets were injected into GPIIb-/- mice just prior to administration of DCF-
labeled B16-D5. IVM was performed immediately and after 1 hour. e) Number of metastatic events was quantified. Results are given as
percentage of firmly adherent B16-D5 in GPIIb-/- littermates receiving GPIIb-/- platelets (n = 4; *P<0.05). f) Size of B16-aggregates was
quantified. Results are given as percentage of B16-aggregate size in GPIIb-/- littermates receiving GPIIb-/- platelets (n = 3; P = n.s.).
doi:10.1371/journal.pone.0172788.g002
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GPIIb does not impact on extravascular tumor growth
The experiments described above focused on hematogenic metastasis formation. To further
assess the role of GPIIb in tumor growth, B16-D5 cells were injected subcutaneously in the
dorsal skin of WT and GPIIb-deficient mice. Tumor size in both groups increased over time
and the growth curves largely overlapped (Fig 3G). After 21 days, explant tumor weight was
not significantly different between GPIIb+/+ (0.551 ± 0.14 g) and GPIIb-/- (0.608 ± 0.21 g) (Fig
3H). These results demonstrate that the effect of GPIIb was restricted to formation for hemato-
genic metastases.
Discussion
Platelet involvement in hematogenic cancer metastasis has been recognized for several years,
however their exact role in this process remains controversial [21]. While some studies have
indicated that inhibition of platelet adhesion receptors or platelet depletion provides protec-
tion against metastatic tumor dissemination [17], others reported that targeted inhibition of
certain platelet surface receptors may even result in enhanced experimental tumor metastasis
[18]. Current data imply that the role of platelets in tumor metastasis is more complex than
initially anticipated. In particular, the impact of platelets on distinct, sequential steps in the cas-
cade of tumor metastasis have not been elucidated, in part because until recently metastatic
organ sites such as the lung were not accessible to direct in vivo examination.
In the present study we used intravital confocal fiber bundle microscopy to directly visual-
ize initial tumor cell seeding in a mouse melanoma model of hematogenic metastasis. We
found that melanoma cells were recruited to the lungs in form of tumor cells aggregates, which
had been cross-linked by blood platelets in a process involving GPIIb-IIIa. This platelet-medi-
ated coaggregation of blood-borne tumor cells significantly increased their ability to home to
the pulmonary microcirculation. While platelets in this way promoted initial micrometastasis,
they attenuated subsequent tumor cell proliferation and growth to macrometastases. Corre-
spondingly, mice with defective tumor-platelet aggregation due to genetic ablation of GPIIb-
IIIa integrin revealed attenuated initial micromatastasis but enlarged pulmonary melanoma
macrometastases ten days after tumor cell infusion.
Previously, it was assumed that tumor cells accumulate in target tissues primarily as single
cells that directly adhere to the vascular wall. Indeed earlier evidence suggests that melanoma
cells have the capacity to firmly adhere to components of the subendothelial matrix under
dynamic flow conditions [42]. However, during dissemination in the pulmonary microcircula-
tion tumor cells most likely encounter an intact pulmonary endothelial monolayer, rather than
exposed extracellular matrix proteins. In vitro, melanoma cell lines are also able to adhere to
Fig 3. Effect of platelet GPIIb on melanoma metastasis formation. a)-c) B16-D5 melanoma cells were injected intravenously
into GPIIb+/+ or GPIIb-/- littermate mice. After 10 days, metastasis formation was analyzed. a) Photomicrographs show represent-
ative lung images. Bars, 0.5 cm. b) Quantification of metastatic nodules in the lung (n = 5; *P<0.05). Boxes indicate median,
whiskers indicate min and max values. c) Quantification of Pmel mRNA expression. Individual Pmel data normalized to beta-
actin is indicated as 2(-ΔCt) (n = 5; *P<0.05). Boxes indicate median, whiskers indicate min and max values. d-e) Pulmonary
melanoma proliferation was determined by analyzing Ki67 expression in HMB-45-positive melanoma cells 10 days after
intravenous seeding (n = 5; *P<0.05). Photomicrographs show fluorescence microscopy images of mouse lung tissue stained
with antibodies directed against melanoma HMB-45 (green) and Ki67 (red); nuclei were stained with DAPI (blue). Images show
3μm optical sections. Left image, overview of lung tissue section; right image, magnification. Bars, 100μm. Images were taken
using a Leica DMRB epifluoresence microscope, 20x and 40x objective. f) Effect of platelets on M21 mitogenesis in vitro. Serum-
starved M21 cells were grown in the absence or presence of increasing concentrations of washed human platelet and BrdU
uptake was quantified (*P<0.05, **P<0.01). g-h) Effect of platelet GPIIb on subcutaneous melanoma growth. g) B16-D5 cells
were injected subcutaneously in the right flank of wildtype and GPIIb-/- littermate mice and tumor growth surveyed using a digital
scaliper. h) 21 days after tumor cell seeding tissues were explanted. Tumor weight was measured indicating no difference in
subcutaneous tumor growth (P = n.s.).
doi:10.1371/journal.pone.0172788.g003
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endothelial cells in a process involving αvβ3 integrin [42, 43], α4β1-integrin, endothelial
VCAM-1, Lu-ECAM-1, as well as the chemokines, including CXCL12 [44, 45]. However, so
far melanoma cell-endothelial cell interactions were tested mostly under low venous flow con-
ditions, which predominate in microcapillaries and postcapillary venules [37]. Consistent with
previous reports [6], we observed in vivo that melanoma cells are recruited mostly to precapil-
lary arterioles, rather than accumulating in postcapillary venules (authors unpublished obser-
vation). Yet, when we exposed melanoma cells to shear conditions typical for precapillary
vascular segments, only few M21 cells managed to adhere to an endothelial monolayer. Hence,
adhesion of individual melanoma cells to the endothelium is unlikely to contribute substan-
tially to melanoma cell seeding in the lungs. Instead our data indicate that the entrapment of
tumor cells aggregates tied up by platelets in a GPIIb-IIIa-dependent manner is the primary
mode of metastatic seeding.
GPIIb-IIIa, the platelet fibrinogen receptor, was required for the formation of melanoma
cell-platelet aggregates. Correspondingly, loss or inhibition of platelet GPIIb-IIIa abolished
tumor cell-platelet interaction. Although GPIIb-IIIa expression was reported in some malig-
nant cell lines [40, 41], we excluded any potential contribution from non-platelet expressed
GPIIb-IIIa: (1) neither M21 nor B16-D5 melanoma cells used in this study express GPIIb-IIIa
and (2) the in vivo defect in melanoma cell aggregation and pulmonary retention in GPIIb-/-
mice could be rescued by infusion of wildtype platelets. Further we excluded that GPIIb-/-
platelets revealed alterations in GPIb-IX-V or GPVI adhesion receptor expression or indicated
impaired platelet activation (S2A–S2C Fig). Although previous studies addressed a potential
contribution of platelet GPIIb-IIIa for hematogenic tumor cell dissemination, these studies
were limited in that they used antibodies or GPIIIa-deficient transgenic mice in order to define
the role of GPIIb-IIIa [46]. While the GPIIb-IIIa receptor complex is platelet-specific, the
GPIIIa (ß3 integrin) subunit also associates with another α subunit to form the vitronectin
receptor (αvß3 integrin), expressed by endothelial cells, osteoclasts, and other cells including
some tumor cells (reviewed in [47]). In contrast GPIIb (αIIb integrin) does not associate with
other subunits than GPIIIa. Furthermore, antibodies such as 10E5 and 7E3 or the F(ab’)2 vari-
ant of 7E3, bind to both GPIIb and GPIIIa on cells [48]. Hence, our present study is the first to
specifically demonstrate a role for platelet GPIIb-IIIa in the context of hematogenic melanoma
metastasis. Consistent with previous reports [8], our present findings suggest that platelet
GPIIb-IIIa integrin associates with αvβ3-integrin, abundantly expressed by M21 and B16-D5
melanoma cells. Accordingly, depletion of GPIIb, function-blocking antibodies to GPIIb-IIIa
integrin or depletion of αvβ3-integrin in M21L virtually abolished the formation of platelet-
tumor cell interactions under flow conditions.
Once attached to circulating tumor cells in a GPIIb-dependent manner, platelets not only
support arrest by formation of platelet-melanoma-aggregates which are retained in the pulmo-
nary vasculature. Platelets also establish a microenvironment that may modulate tumor cell
proliferation and angiogenesis [15, 49]. Although defective platelet-tumor cell interaction due
to loss of GPIIb impaired initial tumor cell retention, it led to a marked increase in tumor bur-
den 10 days after hematogenic pulmonary metastasis. This is an unexpected finding as previ-
ous reports using blocking antibodies directed against GPIIb-IIIa in rodents reported an
inhibitory effect on tumor growth [18, 50]. However, with off-target modulation of integrins
other than platelet GPIIb-IIIa, antibody treatment may not reveal the exact role of platelet
GPIIb-IIIa in cancer metastasis. In fact, our present findings are consistent with the recent
observation that the absence of the platelet receptor GPIbα leads to enhanced cancer metastasis
10 days after melanoma injection [18]. A similar observation was made in mice deficient in von
Willebrand factor, a multimeric glycoprotein that mediates blood coagulation and platelet adhe-
sion via GPIbα and GPIIb-IIIa [51]. While in the latter studies the underlying mechanisms
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remained elusive, we report here that platelets critically inhibit melanoma growth. In lung tissue
sections, analysis of Ki67 expression revealed a reduction in melanoma cell proliferation in ani-
mals with wildtype GPIIb-IIIa compared to GPIIb deficient littermates. However, this observa-
tion was clearly dependent on the pathological setting as subcutaneous tumor growth was not
affected by the absence of GPIIb-IIIa.
In conclusion, we identify GPIIb-IIIa—an important platelet receptor—to differentially affect
initial and subsequent steps of experimental pulmonary metastasis. Visualizing pulmonary micro-
metastasis in vivo, we demonstrate that platelet-specific GPIIb mediates the formation of platelet-
tumor cell aggregates, which are captured in the pulmonary (micro-) circulation. While GPIIb in
this way supports initial steps in pulmonary metastasis, GPIIb-mediated platelet-melanoma cell
colocalization hampers subsequent tumor cell proliferation and impedes the development of mel-
anoma macrometastases. Together, platelet fibrinogen receptor GPIIb-IIIa modulates distinct,
sequential steps in the cascade of hematogenic metastasis with oppositional effects. The data eluci-
date numerous conflicting reports on the role of platelet function in melanoma metastasis and
support our understanding of platelet-driven effects in melanoma biology.
Supporting information
S1 Fig. Surface expression analysis of melanoma cells. Mouse B16-D5 and M21 melanoma
cells were assessed by flow cytometry for their surface expression of the integrins αIIb (GPIIb,
CD41), αv (CD51), β3 (CD61) or IgG isotype control (rat IgG2b for mouse B16-D5, and mouse
IgG1 for human M21) (n = 2–6, mean + SD).
(PDF)
S2 Fig. Receptor expression and activation of murine platelets. Washed platelets prepara-
tions were generated from GPIIb+/+ and GPIIb-/- mice and analysed by flow cytometry (n = 4).
A) Surface expression of the integrins αIIb (GPIIb, CD41) and β3 (CD61), the glycoproteins
Ib, IX and VI, and IgG isotype control stainings were measured. B-C) Comparison of P-selec-
tin (CD62P) (B) and Annexin V (C) surface expression after Thrombin (0.1 U/mL) stimula-
tion.
(PDF)
S3 Fig. Schematic for intravital imaging. Mice were anesthetized and intravenously infused
with DCF-tagged B16-D5. Using confocal laser scanning fibre bundle microscopy we directly
visualized the DCF-tagged tumor cells in vivo. A flexible fibre bundle microprobe with a maxi-
mal optical penetration depth of 150μm was placed on the lung surface. The vasculature of the
dorsal, ventral and basal pulmonary margin of each mouse was visualized as indicated in the
schematic.
(PDF)
S4 Fig. Control staining of lung tissue sections. Immunohistochemistry with isotype control
antibodies for HMB45 and Ki67. Nuclei were stained with DAPI (blue). Images were taken
with 20-fold magnifications. Images were taken using a Leica DMRB epifluoresence micro-
scope, 20x objective.
(PDF)
S1 Videos. Intravital microscopy of melanoma cells in the pulmonary vasculature.DCF-
tagged B16-D5 melanoma cells were visualized in the pulmonary vasculature by intravital
confocal videofluorescence microscopy (IVM) in GPIIb+/+ and GPIIb-/- littermate mice
after 1 hour. Images were taken using a Cellvizio confocal laser scanning fibre bundle micro-
scope with a MiniO Proflex microprobe. Optical penetration depth was 150μm. a) Imaging of
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GPIIb+/+ (WT) mouse, b) GPIIb-/- littermate.
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